Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors

• US 20060293309A1
• Filed: 03/27/2006
• Published: 12/28/2006
• Est. Priority Date: 03/28/2005
• Status: Abandoned Application

• Current Assignee: Edusa Pharmaceuticals, Inc.
• Original Assignee: Dynogen Pharmaceuticals, Inc. (Edusa Pharmaceuticals, Inc.)
• Inventors: Thor, Karl Bruce, Ricca, Daniel J.
• Application Number:
  US11/389,887
• Publication Number:
  US 20060293309A1
• Time in Patent Office: Days
• US Class Current: 514/218
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/551 having two nitrogen atoms, e.g. dilazep

Abstract

The instant invention features compounds, for example, 5-HT₃ receptor antagonists, having a peripherally restricted mode of action such that the compounds affect 5-HT₃ receptors of the peripheral nervous system with diminished or reduced effects in the central nervous system. The compounds are particularly useful in treating disorders or conditions ameliorated by antagonism of peripheral 5-HT₃ receptors. Moreover, side-effects attributable to antagonism of central 5-HT₃ receptors can be lessened or reduced using the peripherally restricted compounds of the invention.

Claims

1. A method for treating, preventing or reducing one or more 5-HT₃ mediated disorders in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of:

(a) a quaternary ammonium derivative of MCI-225 (MCI-225-QUAT);

(b) a quaternary ammonium derivative of MCI-225 (MCI-225-QUAT) possessing an enhanced therapeutic profile;

(c) a peripherally-restricted 5-HT₃ receptor antagonist together with an additional agent for treating, preventing or reducing the one or more 5-HT₃ mediated disorders in the subject;

(d) a peripherally-restricted 5-HT₃ receptor antagonist possessing an enhanced therapeutic profile together with an additional agent for treating, preventing or reducing the one or more 5-HT₃ mediated disorders in the subject; and

(e) a peripherally-restricted 5-HT₃ receptor antagonist together with an additional agent for treating, preventing or reducing the one or more 5-HT₃ mediated disorders in the subject, wherein the peripherally-restricted 5-HT₃ receptor antagonist possesses an enhanced therapeutic profile resulting from the combination of the peripherally-restricted 5-HT₃ receptor antagonist with the additional agent.

2. The method of claim 1, wherein the 5-HT3 mediated disorder is selected from the group consisting of functional bowel disorder, symptoms of a lower urinary tract disorder, nausea, vomiting, retching, overactive bladder (OAB), stress urinary incontinence, pain, fibromyalgia and depressive conditions, obesity and weight gain, pre-menstrual syndrome, eating disorders, migraine, Parkinson'"'"'s disease, stroke, schizophrenia, obsessive-compulsive disorder, fatigue, and any combination thereof.

3-18. -18. (canceled)

19. A method for treating one or more 5-HT3 mediated disorders in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of

(a) a compound of Formula I:

or a pharmaceutically acceptable salt thereof;

(b) a compound of Formula II;

or a pharmaceutically acceptable salt thereof; and

(c) a compound of Formula III;

or a pharmaceutically acceptable salt thereof.

20. The method of claim 19, wherein R₁ is a C₁-C₆ alkyl group and Ar is a substituted phenyl.

21. The method of claim 19, wherein the substituted phenyl group is substituted with a halogen.

22. The method of claim 19, wherein n is 2, R₁ is a C₁-C₆ alkyl group and Ar is phenyl substituted with fluorine.

23. The method of claim 19, wherein n is 2, the substituted phenyl group is substituted with a halogen and R₁ is a methyl group.

24. The method of claim 19, wherein R₂ is hydrogen.

25. The method of claim 19, wherein, if present, R¹ is CH₃, R₂ is H, Ar is 2-fluoro-phenylene, R³ and R⁴ are H, R⁵ and R⁶ are CH₃, n is 2, A⁻

is I⁻

, Z is N⁺(C_1-4)₂, and Y is a quaternary ammonium salt, the salt of a carboxylic acid, the salt of a sulfonic acid, or the salt of a phosphoric acid.

26. The method of claim 19, wherein the 5-HT₃ mediated disorder is selected from the group consisting of functional bowel disorder, symptoms of a lower urinary tract disorder, nausea, vomiting, retching, overactive bladder (OAB), stress urinary incontinence, pain, fibromyalgia and depressive conditions, obesity and weight gain, pre-menstrual syndrome, eating disorders, migraine, Parkinson'"'"'s disease, stroke, schizophrenia, obsessive-compulsive disorder, fatigue, and any combination thereof.

27-30. -30. (canceled)

31. A packaged pharmaceutical composition for treating one or more 5-HT₃ mediated disorders in a subject, comprising a container holding a therapeutically effective amount of a peripherally-restricted 5-HT₃ receptor antagonist;

and instructions for using the composition for treating the one or more 5-HT₃ mediated disorders in the subject.

32. The packaged pharmaceutical composition of claim 31, further comprising an additional agent for treating the one or more 5-HT₃ mediated disorders thereof in the subject.

33. The packaged pharmaceutical of claim 31, wherein the 5-HT₃ mediated disorder is selected from the group consisting of functional bowel disorder, symptoms of a lower urinary tract disorder, nausea, vomiting, retching, overactive bladder (OAB), stress urinary incontinence, pain, fibromyalgia and depressive conditions, obesity and weight gain, pre-menstrual syndrome, eating disorders, migraine, Parkinson'"'"'s disease, stroke, schizophrenia, obsessive-compulsive disorder, fatigue, and any combination thereof.

34. A pharmaceutical composition for treating one or more 5-HT₃ mediated disorders in a subject, comprising a compound selected from the group consisting of:

(a) a peripherally-restricted 5-HT₃ receptor antagonist selected based on its peripheral restriction,

(b) an MCI-225-QUAT;

(c) an MCI-225-QUAT possessing an enhanced therapeutic profile; and

(d) a peripherally-restricted 5-HT₃ receptor antagonist together with an additional agent for treating the one or more 5-HT₃ mediated disorders in the subject;

and a pharmaceutically acceptable carrier.

38. The pharmaceutical composition of claim 34, wherein the 5-HT₃ mediated disorder is selected from the group consisting of functional bowel disorder, symptoms of a lower urinary tract disorder, nausea, vomiting, retching, overactive bladder (OAB), stress urinary incontinence, pain, fibromyalgia and depressive conditions, obesity and weight gain, pre-menstrual syndrome, eating disorders, migraine, Parkinson'"'"'s disease, stroke, schizophrenia, obsessive-compulsive disorder, fatigue, and any combination thereof.

35-37. -37. (canceled)

39. A method for treating a functional bowel disorder in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of:

(a) a quaternary ammonium derivative of MCI-225 (MCI-225-QUAT);

(b) a peripherally-restricted 5-HT₃ receptor antagonist together with an additional agent for treating the functional bowel disorder in the subject; and

(c) a peripherally-restricted 5-HT₃ receptor antagonist together with a noradrenaline reuptake inhibitor.

40. The method of claim 39, wherein the functional bowel disorder is selected from the group consisting of (a) irritable bowel syndrome, (b) diarrhea-predominant irritable bowel syndrome, (c) alternating constipation/diarrhea irritable bowel syndrome, and (d) nonconstipated irritable bowel syndrome.

41-59. -59. (canceled)

60. A method for treating a functional bowel disorder in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of

(a) a compound of Formula I:

or a pharmaceutically acceptable salt thereof;

(b) a compound of Formula II;

or a pharmaceutically acceptable salt thereof; and

(c) a compound of Formula III;

or a pharmaceutically acceptable salt thereof.

61. The method of claim 60, wherein R₁ is a C₁-C₆ alkyl group and Ar is a substituted phenyl.

62. The method of claim 60, wherein the substituted phenyl group is substituted with a halogen.

63. The method of claim 60, wherein n is 2, R₁ is a C₁-C₆ alkyl group and Ar is phenyl substituted with fluorine.

64. The method of claim 60, wherein n is 2, the substituted phenyl group is substituted with a halogen and R₁ is a methyl group.

65. The method of claim 60, wherein R₂ is hydrogen.

66. The method of claim 60, wherein, if present, R¹ is CH₃, R₂ is H, Ar is 2-fluoro-phenylene, R³ and R⁴ are H, R⁵ and R⁶ are CH₃, n is 2, A⁻

is I⁻

, Z is N⁺(C_1-4)₂, and Y is a quaternary ammonium salt, the salt of a carboxylic acid, the salt of a sulfonic acid, or the salt of a phosphoric acid.

67. A method of treating at least one symptom of a lower urinary tract disorder in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a quaternary ammonium derivative of MCI-225 (MCI-225-QUAT).

68-82. -82. (canceled)

83. A method of treating at least one symptom of a lower urinary tract disorder in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of

(a) a compound of Formula I:

or a pharmaceutically acceptable salt thereof,

(b) a compound of Formula II;

or a pharmaceutically acceptable salt thereof, and

(c) a compound of Formula III;

or a pharmaceutically acceptable salt thereof.

84. The method of claim 83, wherein R₁ is a C₁-C₆ alkyl group and Ar is a substituted phenyl.

85. The method of claim 83, wherein the substituted phenyl group is substituted with a halogen.

86. The method of claim 83, wherein n is 2, R₁ is a C₁-C₆ alkyl group and Ar is phenyl substituted with fluorine.

87. The method of claim 83, wherein n is 2, the substituted phenyl group is substituted with a halogen and R₁ is a methyl group.

88. The method of claim 83, wherein R₂ is hydrogen.

89. The method of claim 83, wherein, if present, R¹ is CH₃, R₂ is H, Ar is 2-fluoro-phenylene, R³ and R⁴ are H, R⁵ and R⁶ are CH₃, n is 2, A⁻

is I⁻

, Z is N⁺(C_1-4)₂, and Y is a quaternary ammonium salt, the salt of a carboxylic acid, the salt of a sulfonic acid, or the salt of a phosphoric acid.

90. A method for treating urinary incontinence in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of:

(a) a quaternary ammonium derivative of MCI-225 (MCI-225-QUAT);

(b) a quaternary ammonium derivative of MCI-225 (MCI-225-QUAT) possessing an enhanced therapeutic profile;

(c) a peripherally-restricted 5-HT₃ receptor antagonist together with an additional agent for treating the urinary incontinence in the subject; and

(d) a peripherally-restricted 5-HT₃ receptor antagonist together with a noradrenaline reuptake inhibitor.

138. The method of claim 90, wherein the urinary incontinence is stress urinary incontinence.

91. (canceled)

92. A method for treating nausea, vomiting, retching or any combination thereof in a subject in need thereof comprising administering to said subject a therapeutically effective amount of (a) a quaternary ammonium derivative of MCI-225 (MCI-225-QUAT);

or (b) a quaternary ammonium derivative of MCI-225 (MCI-225-QUAT) possessing an enhanced therapeutic profile.

94. The method of claims 92, wherein the nausea, vomiting, retching or any combination thereof is caused by an anesthetic, radiation, a cancer chemotherapeutic agent, a toxic agent, an odor, a medicine, pregnancy or motion.

95. The method of claim 92, wherein the medicine is selected from the group consisting of an analgesic, an antibiotic, an antifungal, a serotonin reuptake inhibitor, or a dual serotonin-norepinephrine reuptake inhibitor (SNRI).

96. The method of claim 94, wherein the nausea, vomiting, retching or any combination thereof is caused by (a) a condition which is associated with vertigo, (b) headache, or (c) a malady of the gastrointestinal (GI) tract.

100. The method of claim 92, wherein the nausea, vomiting, retching or any combination thereof is chronic functional vomiting.

93. (canceled)

97-99. -99. (canceled)

101-115. -115. (canceled)

116. A method for treating nausea, vomiting, retching or any combination thereof in a subject in need thereof comprising administering to said subject a t therapeutically effective amount of a compound selected from the group consisting of

(a) a compound of Formula I:

or a pharmaceutically acceptable salt thereof;

(b) a compound of Formula II;

or a pharmaceutically acceptable salt thereof; and

(c) a compound of Formula III;

or a pharmaceutically acceptable salt thereof.

117. The method of claim 116, wherein R₁ is a C₁-C₆ alkyl group and Ar is a substituted phenyl.

118. The method of claim 116, wherein the substituted phenyl group is substituted with a halogen.

119. The method of claim 116, wherein n is 2, R₁ is a C₁-C₆ alkyl group and Ar is phenyl substituted with fluorine.

120. The method of claim 116, wherein n is 2, the substituted phenyl group is substituted with a halogen and R₁ is a methyl group.

121. The method of claim 116, wherein R₂ is hydrogen.

122. The method of claim 116, wherein, if present, R¹ is CH₃, R₂ is H, Ar is 2-fluoro-phenylene, R³ and R⁴ are H, R⁵ and R⁶ are CH₃, n is 2, A⁻

is I⁻

, Z is N⁺(C_1-4)₂, and Y is a quaternary ammonium salt, the salt of a carboxylic acid, the salt of a sulfonic acid, or the salt of a phosphoric acid.

123-129. -129. (canceled)

130. A method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment, wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, nocturia and enuresis, comprising coadministering to said subject a peripherally-restricted 5-HT₃ receptor antagonist with an additional agent.

131. The method of claim 130, wherein the additional agent is a noradrenaline reuptake inhibitor.

132. The method of claim 130, wherein the lower urinary tract disorder is selected from the group consisting of overactive bladder, interstitial cystitis, prostatitis, prostadynia and benign prostatic hyperplasia.

133-137. -137. (canceled)

139. (canceled)

140. A method for treating nausea, vomiting, retching or any combination thereof in a subject in need thereof comprising administering to said subject a compound selected from the group consisting of:

(a) a peripherally-restricted 5-HT₃ receptor antagonist together with an additional agent for treating the nausea, vomiting, retching or any combination thereof in the subject;

(b) a peripherally-restricted 5-HT₃ receptor antagonist together with a noradrenaline reuptake inhibitor;

(c) a peripherally-restricted 5-HT₃ receptor antagonist selected based on its peripheral restriction; and

(d) a peripherally-restricted 5-HT₃ receptor antagonist together with an additional agent, wherein the additional agent is selected based on its effect in combination with the peripherally-restricted 5-HT₃ receptor antagonist for treating the nausea, vomiting, retching or any combination thereof in the subject.

144. The method of claims 140, wherein the nausea, vomiting, retching or any combination thereof is chronic functional vomiting.

141-143. -143. (canceled)

145-159. -159. (canceled)

160. A compound selected from the group consisting of

(a) Formula I:

or a pharmaceutically acceptable salt thereof;

(b) Formula II;

or a pharmaceutically acceptable salt thereof; and

(c) Formula III;

or a pharmaceutically acceptable salt thereof.

161. The compound of claim 160, wherein R₁ is a C₁-C₆ alkyl group and Ar is a substituted phenyl.

162. The compound of claim 160, wherein the substituted phenyl group is substituted with a halogen.

163. The compound of claim 160, wherein n is 2, R₁ is a C₁-C₆ alkyl group and Ar is phenyl substituted with fluorine.

164. The compound of claim 160, wherein n is 2, the substituted phenyl group is substituted with a halogen and R₁ is a methyl group.

165. The compound of claim 160, wherein R₂ is hydrogen.

166. The compound of claim 160, wherein, if present, R₁ is CH₃, R₂ is H, Ar is 2-fluoro-phenylene, R³ and R⁴ are H, R⁵ and R⁶ are CH₃, n is 2, A⁻

is I⁻

, Z is N⁺(C_1-4)₂, and Y is a quaternary ammonium salt, the salt of a carboxylic acid, the salt of a sulfonic acid, or the salt of a phosphoric acid.

167. A packaged pharmaceutical composition for treating a functional bowel disorder in a subject, comprising a container holding a therapeutically effective amount of a peripherally-restricted 5-HT₃ receptor antagonist;

and instructions for using the composition for treating the functional bowel disorder in the subject.

168. The packaged pharmaceutical composition of claim 167 further comprising an additional agent for treating the functional bowel disorder in the subject.

169. A pharmaceutical composition for treating a functional bowel disorder in a subject, comprising a compound selected from the group consisting of:

(a) a peripherally-restricted 5-HT₃ receptor antagonist selected based on its peripheral restriction;

(b) an MCI-225-QUAT;

(c) an MCI-225-QUAT possessing an enhanced therapeutic profile; and

(d) a peripherally-restricted 5-HT₃ receptor antagonist together with an additional agent for treating the functional bowel disorder in the subject;

and a pharmaceutically acceptable carrier.

173. The pharmaceutical composition of claim 169, wherein the functional bowel disorder is selected from the group consisting of (a) irritable bowel syndrome, (b) diarrhea-predominant irritable bowel syndrome, (c) alternating constipation/diarrhea irritable bowel syndrome, and (d) nonconstipated irritable bowel syndrome.

170-172. -172. (canceled)

174-176. -176. (canceled)

177. (canceled)

178. A packaged pharmaceutical composition for treating at least one symptom of a lower urinary tract disorder in a subject, comprising a container holding a therapeutically effective amount of a peripherally-restricted 5-HT₃ receptor antagonist;

and instructions for using the composition for treating the at least one symptom of a lower urinary tract disorder in the subject.

179. The packaged pharmaceutical composition of claim 178, further comprising an additional agent for treating the at least one symptom of a lower urinary tract disorder in the subject.

180. A pharmaceutical composition for treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment, comprising a compound selected from the group consisting of:

(a) a peripherally-restricted 5-HT₃ receptor antagonist selected based on its peripheral restriction;

(b) an MCI-225-QUAT;

(c) an MCI-225-QUAT possessing an enhanced therapeutic profile; and

(d) a peripherally-restricted 5-HT₃ receptor antagonist together with an additional agent for treating the at least one symptom of a lower urinary tract disorder in the subject;

and a pharmacuetically acceptable carrier,

wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, nocturia and enuresis.

184. The pharmaceutical composition of claim 180, wherein the lower urinary tract disorder is selected from the group consisting of overactive bladder, interstitial cystitis, prostatitis, prostadynia and benign prostatic hyperplasia.

181-183. -183. (canceled)

185-187. -187. (canceled)

188. A packaged pharmaceutical composition for treating urinary incontinence in a subject, comprising a container holding a therapeutically effective amount of a peripherally-restricted 5-HT₃ receptor antagonist;

and instructions for using the composition for treating urinary incontinence in a subject.

189. The packaged pharmaceutical composition of claim 188-together with an additional agent for treating urinary incontinence in a subject.

190. A pharmaceutical composition for treating urinary incontinence in a subject in need thereof, comprising a compound selected from the group consisting of:

(a) a peripherally-restricted 5-HT₃ receptor antagonist selected based on its peripheral restriction;

(b) an MCI-225-QUAT;

(c) an MCI-225-QUAT possessing an enhanced therapeutic profile;

(d) a peripherally-restricted 5-HT₃ receptor antagonist together with an additional agent for treating the urinary incontinence in the subject;

and a pharmaceutically acceptable carrier.

194. The pharmaceutical composition of claim 190, wherein the urinary incontinence is stress urinary incontinence.

191-193. -193. (canceled)

195. (canceled)

196. A packaged pharmaceutical composition for treating nausea, vomiting, retching or any combination thereof in a subject, comprising a container holding a therapeutically effective amount of a peripherally-restricted 5-HT₃ receptor antagonist;

and instructions for using the composition for treating the nausea, vomiting, retching or any combination thereof in the subject.

197. The packaged pharmaceutical composition of claim 196, together with an additional agent for treating the nausea, vomiting, retching or any combination thereof in the subject.

198. A pharmaceutical composition for treating nausea, vomiting, retching or any combination thereof in a subject, comprising a compound selected from the group consisting of:

(a) a peripherally-restricted 5-HT₃ receptor antagonist selected based on its peripheral restriction;

(b) an MCI-225-QUAT;

(c) an MCI-225-QUAT possessing an enhanced therapeutic profile;

(d) a peripherally-restricted 5-HT₃ receptor antagonist together with an additional agent for treating the nausea, vomiting, retching or any combination thereof in the subject;

(e) a peripherally-restricted 5-HT₃ receptor antagonist selected based on its peripheral restriction together with an additional agent for treating the nausea, vomiting, retching or any combination thereof in the subject; and

(f) a peripherally-restricted 5-HT₃ receptor antagonist selected based on its peripheral restriction together with an additional agent for treating the nausea, vomiting, retching or any combination thereof in the subject, wherein the additional agent is selected based on its effect in combination with the peripherally-restricted 5-HT₃ receptor antagonist;

and a pharmaceutically acceptable carrier.

204. The pharmaceutical composition of claim 198, wherein the nausea, vomiting, retching or any combination thereof is caused by an anesthetic, radiation, a cancer chemotherapeutic agent, a toxic agent, an odor, a medicine, pregnancy or motion.

205. The pharmaceutical composition of claim 204, wherein the medicine is selected from the group consisting of an analgesic, an antibiotic, an antifungal, a serotonin reuptake inhibitor, or a dual serotonin-norepinephrine reuptake inhibitor (SNRI).

206. The pharmaceutical composition of claim 198, wherein the nausea, vomiting, retching or any combination thereof is caused by (a) a condition which is associated with vertigo, (b) headache, or (c) a malady of the gastrointestinal (GI) tract.

209. The pharmaceutical composition of claim 198, wherein the nausea, vomiting, retching or any combination thereof is chronic functional vomiting.

199-203. -203. (canceled)

207-208. -208. (canceled)

210. (canceled)